HGH Fragment 176-191
HGH Fragment 176-191 corresponds to the C-terminal lipolytic region of human growth hormone.
- Vial Size
- 5mg
- Molecular Weight
- 1817.1 g/mol
- Half-life
- ~15–30 minutes
- Latest Lot Purity
- 99.62%
Mechanism of Action
HGH Fragment 176-191 corresponds to the C-terminal lipolytic region of human growth hormone. Research focuses on selective stimulation of adipose lipolysis without the IGF-1 cascade associated with full-length GH.
Research Context
- Lipolysis and adipose tissue research
- Body-composition study models
- Metabolic signalling assays
- GH-fragment pharmacology
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Plasma Profile & Protocol
Modelled plasma concentration over time, reconstitution calculator, and a literature-derived research protocol for HGH Fragment 176-191.
Illustrative Bateman model derived from published half-life and absorption data. For research-context visualisation only.
Solve for syringe units assuming a U-100 insulin syringe. Defaults seeded from the HGH Fragment 176-191 monograph.
U-100 insulin syringe assumed (100 units = 1 mL). For research dosing visualisation only. Verify all dilutions independently.
- Typical Dose
- 250–500 mcg
- Frequency
- 1–2× daily, pre-fast
- Cycle Length
- 8–12 weeks
- Route
- Subcutaneous
Note ·Short-acting; lipolysis research models often dose pre-cardio.
Related Compounds
All compounds →
CJC 1295 (without DAC) + IPA
Dual-component GH-axis research blend.
Tesamorelin
GHRH analog supporting advanced metabolic and visceral adipose research.
Ipamorelin
Selective growth hormone secretagogue for protocol layering.
For Research Use Only · This monograph summarises publicly available research literature for educational, in-vitro and laboratory research purposes only. Nexora Labs products are not drugs, food, supplements, or cosmetics, and are not intended to diagnose, treat, cure or prevent any condition.